Kathryn Doyle to Speak at CBI’s Mergers and Acquisitions and Strategic Alliances in Life Sciences Conference

Kathryn Doyle to Speak at CBI’s Mergers and Acquisitions and Strategic Alliances in Life Sciences Conference
Creative Deal-Making & Collaborations: Legal & Transactional Strategies to Create Value & Mitigate Risk
October 14-15, 2015

CBI, a leader in conferences for the pharmaceutical industry, is hosting interactive discussions on the legal and business nuances of creative deal-making, licensing and collaboration strategies.

In Q1, there were 35 deals completed, representing deal value of $166.3 billion, a value higher than 2014 total deals alone and there’s no sign of a slowdown. Rising equity valuations, historically low interest rates and the demand to use deal-making to add revenue growth and/or business focus all continue to fuel this explosive uptick in deals.

Learn the latest deal-making strategies from a legal and business perspective — from our esteemed faculty of leading life sciences transactions lawyers and business development executives. Our experts get you proficient in the different deal-making options available — life sciences mergers, acquisitions, collaborations and licensing agreements — including various legal implications and how your alliances can create value, while mitigating risk.

Saul Ewing partner, Kathryn Doyle, will speak about “Assessing the Strength of a Target’s Intellectual Property Portfolio and the Impact on Deal-Making.”

The conference will take place October 14th and 15th at The Ritz Carlton in Philadelphia, PA.

For more information, click here.

Blog Entries